At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
sipuleucel-Tbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating sipuleucel-T for Prostate Cancer. Completed, enrolled 104 participants across 18 sites.
Detailed Summary
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartOct 2009
Primary CompletionDec 2014
Study CompletionJun 2015
TodayJul 2026
First PostedMay 13, 2009
Enrollment StartOct 1, 2009
Primary CompletionDec 1, 2014
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 17.1 years ago
Interventions
sipuleucel-Tbiological
Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)